Crinetics Pharmaceuticals, Inc. (CRNX) Return on equity 2018–2025
Crinetics Pharmaceuticals, Inc. (CRNX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-46.9%FY2025 · since FY2018: -16.9% → -46.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -46.9% | -24.4 pp |
| FY2024 | -22.5% | +17.3 pp |
| FY2023 | -39.8% | +12.0 pp |
| FY2022 | -51.8% | -19.4 pp |
| FY2021 | -32.4% | +11.3 pp |
| FY2020 | -43.7% | -0.7 pp |
| FY2019 | -43.0% | -26.1 pp |
| FY2018 | -16.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice